Wall Street brokerages expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to post earnings of ($0.53) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.50) and the lowest estimate coming in at ($0.60). Syros Pharmaceuticals reported earnings of ($5.42) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 90.2%. The firm is scheduled to issue its next quarterly earnings results on Monday, August 21st.

On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($2.29) per share for the current year, with EPS estimates ranging from ($2.84) to ($1.99). For the next year, analysts expect that the business will report earnings of ($3.29) per share, with EPS estimates ranging from ($4.15) to ($2.55). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Monday, May 15th. The company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.10. The company had revenue of $1.10 million for the quarter.

A number of brokerages recently commented on SYRS. Oppenheimer Holdings, Inc. set a $28.00 price objective on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, June 12th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Syros Pharmaceuticals in a research report on Tuesday, May 16th. Finally, Zacks Investment Research raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Thursday, March 23rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Syros Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $20.86.

A number of hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in Syros Pharmaceuticals during the first quarter valued at approximately $185,000. Wells Fargo & Company MN acquired a new stake in Syros Pharmaceuticals during the first quarter valued at approximately $225,000. Finally, Redmile Group LLC increased its stake in Syros Pharmaceuticals by 0.5% in the first quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock valued at $15,177,000 after buying an additional 4,300 shares in the last quarter. 49.45% of the stock is owned by institutional investors.

WARNING: “Syros Pharmaceuticals, Inc. (SYRS) Expected to Announce Earnings of -$0.53 Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/06/syros-pharmaceuticals-inc-syrs-expected-to-announce-earnings-of-0-53-per-share.html.

Syros Pharmaceuticals (SYRS) traded up 0.68% during trading on Thursday, reaching $17.79. 23,983 shares of the company’s stock were exchanged. The company’s 50 day moving average price is $16.30 and its 200-day moving average price is $14.00. The stock’s market capitalization is $465.74 million. Syros Pharmaceuticals has a 52 week low of $8.16 and a 52 week high of $21.50.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.